Nothing Special   »   [go: up one dir, main page]

EA200100966A1 - TREATMENT OF THROMBOSIS BY THE COMBINED APPLICATION OF THE INHIBITOR OF THE FACTOR Xa AND ASPIRIN, THE ACTIVATOR OF A TISSUE PLASMINOGEN (TPA), ANTAGONIST GPIIB / IIIA, A LOW-MOLECULAR HEPARIN OR HEPARIN - Google Patents

TREATMENT OF THROMBOSIS BY THE COMBINED APPLICATION OF THE INHIBITOR OF THE FACTOR Xa AND ASPIRIN, THE ACTIVATOR OF A TISSUE PLASMINOGEN (TPA), ANTAGONIST GPIIB / IIIA, A LOW-MOLECULAR HEPARIN OR HEPARIN

Info

Publication number
EA200100966A1
EA200100966A1 EA200100966A EA200100966A EA200100966A1 EA 200100966 A1 EA200100966 A1 EA 200100966A1 EA 200100966 A EA200100966 A EA 200100966A EA 200100966 A EA200100966 A EA 200100966A EA 200100966 A1 EA200100966 A1 EA 200100966A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heparin
gpiib
tpa
aspirin
inhibitor
Prior art date
Application number
EA200100966A
Other languages
Russian (ru)
Inventor
Панкрас К. Вонг
Original Assignee
Дюпон Фармасьютикалз Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дюпон Фармасьютикалз Компани filed Critical Дюпон Фармасьютикалз Компани
Publication of EA200100966A1 publication Critical patent/EA200100966A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описан способ лечения тромбоза у млекопитающих путем введения указанному терапевтически эффективных количеств сочетания (i) ингибитора фактора Xa и (ii) соединения, выбранного из группы, состоящей из аспирина, TPA, антагониста GPIIb/IIIa, низкомолекулярного гепарина и гепарина, в котором вводимая доза, по меньшей мере, одного из (i) и (ii) представляет собой субтерапевтическую дозу. Предпочтительно, сочетание (i) и (ii) обеспечивает синергический эффект.Международная заявка была опубликована вместе с отчетом о международном поиске.A method of treating thrombosis in a mammal is described by administering therapeutically effective amounts of a combination of (i) a factor Xa inhibitor and (ii) a compound selected from the group consisting of aspirin, TPA, a GPIIb / IIIa antagonist, low molecular weight heparin and heparin, in which the dose administered is at least one of (i) and (ii) is a subtherapeutic dose. Preferably, the combination of (i) and (ii) provides a synergistic effect. The international application was published together with an international search report.

EA200100966A 1999-03-11 2000-03-10 TREATMENT OF THROMBOSIS BY THE COMBINED APPLICATION OF THE INHIBITOR OF THE FACTOR Xa AND ASPIRIN, THE ACTIVATOR OF A TISSUE PLASMINOGEN (TPA), ANTAGONIST GPIIB / IIIA, A LOW-MOLECULAR HEPARIN OR HEPARIN EA200100966A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12381599P 1999-03-11 1999-03-11
PCT/US2000/006451 WO2000053264A1 (en) 1999-03-11 2000-03-10 Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin

Publications (1)

Publication Number Publication Date
EA200100966A1 true EA200100966A1 (en) 2002-02-28

Family

ID=22411057

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100966A EA200100966A1 (en) 1999-03-11 2000-03-10 TREATMENT OF THROMBOSIS BY THE COMBINED APPLICATION OF THE INHIBITOR OF THE FACTOR Xa AND ASPIRIN, THE ACTIVATOR OF A TISSUE PLASMINOGEN (TPA), ANTAGONIST GPIIB / IIIA, A LOW-MOLECULAR HEPARIN OR HEPARIN

Country Status (12)

Country Link
EP (1) EP1161279A1 (en)
JP (1) JP2002538226A (en)
KR (1) KR20020005614A (en)
CN (1) CN1346292A (en)
AU (1) AU766089B2 (en)
BR (1) BR0010381A (en)
CA (1) CA2361650A1 (en)
EA (1) EA200100966A1 (en)
IL (1) IL144798A0 (en)
NZ (1) NZ513217A (en)
WO (1) WO2000053264A1 (en)
ZA (1) ZA200106360B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344450B1 (en) 1999-02-09 2002-02-05 Bristol-Myers Squibb Company Lactam compounds and their use as inhibitors of serine proteases and method
WO2000047207A1 (en) 1999-02-09 2000-08-17 Bristol-Myers Squibb Company LACTAM INHIBITORS OF FXa AND METHOD
TWI288745B (en) * 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US6599926B2 (en) * 2000-06-23 2003-07-29 Bristol-Myers Squibb Company Heteroaryl-phenyl substituted factor Xa inhibitors
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
WO2002102325A2 (en) * 2001-02-28 2002-12-27 Griffin John H Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein c
SE0101932D0 (en) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
DE10129725A1 (en) * 2001-06-20 2003-01-02 Bayer Ag Combination therapy of substituted oxazolidinones
EP1455858A4 (en) 2001-11-26 2006-02-15 Genentech Inc Catheter composition and uses thereof
EP1569912B1 (en) 2002-12-03 2015-04-29 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
EP1679067A4 (en) * 2003-09-19 2010-04-07 Kissei Pharmaceutical Concurrent drugs
WO2006083477A2 (en) 2005-01-07 2006-08-10 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2008070353A2 (en) 2006-11-07 2008-06-12 Genentech, Inc. Tissue plasminogen activator variant uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5670494A (en) * 1992-12-01 1994-06-22 Merck & Co., Inc. Anticoagulant proteins
RU2149871C1 (en) * 1993-11-24 2000-05-27 Дзе Дюпон Мерк Фармасьютикал Компани Isoxazolines and isoxazoles, method of inhibition of platelet aggregation, pharmaceutical composition inhibiting platelet aggregation
EP0735050B1 (en) * 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions for inhibiting thrombogenesis
US5610308A (en) * 1995-05-18 1997-03-11 Bristol-Myers Squibb Company Process for preparing intermediates for thrombin inhibitors
US6069130A (en) * 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
WO1998028269A1 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
EP1068172A4 (en) * 1998-02-02 2006-09-27 Merck & Co Inc PLATELET AGGREGATION INHIBITION USING LOW MOLECULAR WEIGHT HEPARIN IN COMBINATION WITH A GP IIb/IIIa ANTAGONIST
WO1999045913A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
DE19816983A1 (en) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma New bicyclic heteroaromatic amidine or nitrile compounds, used as thrombin inhibitors, antithrombotic agents or intermediates

Also Published As

Publication number Publication date
WO2000053264A1 (en) 2000-09-14
CA2361650A1 (en) 2000-09-14
AU766089B2 (en) 2003-10-09
NZ513217A (en) 2003-11-28
AU3525400A (en) 2000-09-28
IL144798A0 (en) 2002-06-30
ZA200106360B (en) 2002-08-02
CN1346292A (en) 2002-04-24
EP1161279A1 (en) 2001-12-12
JP2002538226A (en) 2002-11-12
KR20020005614A (en) 2002-01-17
BR0010381A (en) 2002-02-05

Similar Documents

Publication Publication Date Title
EA200100966A1 (en) TREATMENT OF THROMBOSIS BY THE COMBINED APPLICATION OF THE INHIBITOR OF THE FACTOR Xa AND ASPIRIN, THE ACTIVATOR OF A TISSUE PLASMINOGEN (TPA), ANTAGONIST GPIIB / IIIA, A LOW-MOLECULAR HEPARIN OR HEPARIN
Popma et al. Clinical trials of restenosis after coronary angioplasty.
CY1106149T1 (en) THE USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF SITOSTEPOLEMIA
Esmon Targeting factor Xa and thrombin: impact on coagulation and beyond
EA200100965A1 (en) SYNERGISM BETWEEN LOW MOLECULAR HEPARIN AND INHIBITORS AGAINSTATION OF PLATELETS THAT PROVIDES COMBINED THERAPY FOR PREVENTION AND TREATMENT OF DIFFERENT THROMBOEMBOLIC DISORDERS
ES2097208T3 (en) COMPOSITIONS AND THERAPEUTIC AND SYNERGIC PROCEDURES.
TR199801151T2 (en) Drugs that inhibit thrombin.
AR032403A1 (en) INHIBITOR COMBINATIONS (ES) OF STEROL ABSORPTION WITH BLOOD MODIFIER (ES) TO TREAT VASCULAR TABLES
EA200300953A1 (en) THERAPEUTIC COMBINATIONS FOR USE IN CARDIOVASCULAR AND INFLAMMATORY DISEASES
ECSP074704A (en) INHIBITOR COMBINATIONS (S) OF STEROL ABSORPTION WITH BLOOD MODIFIER (S) TO TREAT VASCULAR TABLES
UY26635A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
ATE282425T1 (en) METHOD FOR TREATING ENDOTHELIAL INJURIES
FI963462A (en) Benzothiophene, benzofuran and indolthiazepinones, oxazepinones and diazepinones as inhibitors of cell adhesion and inhibitors of HIV
EA200400734A1 (en) METHOD AND COMPOSITION FOR POTENTIATING OPIATIVE ANALGETIC ACTION
ATE419857T1 (en) USE OF LAXATIVES TO TREAT IRRITABLE BOWEL SYNDROME
EE200200565A (en) Combination therapy with vascular adverse effects
EA200301015A1 (en) COMBINATION INCLUDING COMBRESTASTATIN AND ANTI-CANCER AGENTS
EA200200995A1 (en) APPLICATION OF AZALIDE ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF BACTERIAL OR PROTOSOIC INFECTIONS IN MAMMALS
EA200200502A1 (en) METHOD OF INTRODUCTION OF PHOSPHODYSTRASE 4 INHIBITOR
Ghigliotti et al. Prolonged activation of prothrombin on the vascular wall after arterial injury
ES2195025T3 (en) FUSION PROTEINS OF A KUNITZ TISSULAR-DOMAIN FACTOR DOMAIN AS INHIBITORS OF THE FACTOR VIIA.
RU95112534A (en) Dermatansulfates and their salts, antithrombosis agents, method of thrombosis prevention and treatment, method of multiple intravascular coagulation syndrome prevention or treatment, method of myocardial infarction treatment
ES2088128T3 (en) ACAT INHIBITOR AMINOSULFONILUREAS.
ATE201823T1 (en) TOPICAL PHARMACEUTICAL COMPOSITIONS CONTAINING HEPARIN
DK0799618T3 (en) Use of alpha1 adrenoreceptor antagonists in the manufacture of a drug for the prevention and treatment of cancer